Related Experiment Video
Updated: Jun 12, 2025

Measuring Mitochondrial Function of Naïve and Effector CD8 T Cells
Published on: March 28, 2025
CXCR4 orchestrates the TOX-programmed exhausted phenotype of CD8+ T cells via JAK2/STAT3 pathway
Canhui Cao1, Miaochun Xu2, Ye Wei1
1Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China; Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430199, China; Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China; National Clinical Research Center for Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
Abstract:
Evidence from clinical trials suggests that CXCR4 antagonists enhance immunotherapy effectiveness in several cancers. However, the specific mechanisms through which CXCR4 contributes to immune cell phenotypes are not fully understood. Here, we employed single-cell transcriptomic analysis and identified CXCR4 as a marker gene in T cells, with CD8+PD-1high exhausted T (Tex) cells exhibiting high CXCR4 expression. By blocking CXCR4, the Tex phenotype was attenuated in vivo. Mechanistically, CXCR4-blocking T cells mitigated the Tex phenotype by regulating the JAK2-STAT3 pathway. Single-cell RNA/TCR/ATAC-seq confirmed that Cxcr4-deficient CD8+ T cells epigenetically mitigated the transition from functional to exhausted phenotypes. Notably, clinical sample analysis revealed that CXCR4+CD8+ T cells showed higher expression in patients with a non-complete pathological response. Collectively, these findings demonstrate the mechanism by which CXCR4 orchestrates CD8+ Tex cells and provide a rationale for combining CXCR4 antagonists with immunotherapy in clinical trials.
Insights
CXCR4 antagonists can improve cancer immunotherapy. This study reveals CXCR4 drives T-cell exhaustion, and blocking it restores immune function, supporting combination therapies.
Area of Science:
- Immunology
- Cancer Biology
- Molecular Medicine
Background:
- Clinical trials indicate CXCR4 antagonists enhance cancer immunotherapy.
- The precise mechanisms of CXCR4's role in immune cell phenotypes remain unclear.
Purpose of the Study:
- To elucidate the role of CXCR4 in CD8+ T-cell exhaustion.
- To investigate the mechanistic pathways regulated by CXCR4 in T-cells.
- To provide a rationale for CXCR4 antagonist combination therapy.
Main Methods:
- Single-cell transcriptomic analysis (scRNA-seq).
- In vivo experiments blocking CXCR4.
- Single-cell RNA/TCR/ATAC-seq.
- Clinical sample analysis.
Main Results:
- CXCR4 is a marker gene in T-cells, highly expressed in exhausted CD8+ T (Tex) cells.
- Blocking CXCR4 in vivo attenuated the Tex phenotype.
- CXCR4 blockade modulated the JAK2-STAT3 pathway.
- Cxcr4-deficient CD8+ T-cells showed epigenetic mitigation of exhaustion.
- Increased CXCR4+CD8+ T-cells correlated with non-complete pathological response in patients.
Conclusions:
- CXCR4 orchestrates the CD8+ Tex cell phenotype.
- CXCR4 antagonists can reverse T-cell exhaustion via the JAK2-STAT3 pathway.
- These findings support combining CXCR4 antagonists with immunotherapy for enhanced efficacy.
Related Concept Videos
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
The JAK-STAT Signaling Pathway
The Extrinsic Apoptotic Pathway
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Anaphase Promoting Complex
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...

